Opaleye Management Inc. Merus N.V. Transaction History

Opaleye Management Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$18.64 - $28.93 $1.58 Million - $2.45 Million	-84,800 Reduced 25.09%	253,200 $5.07 Million
Q1 2022 May 16, 2022	BUY	$23.58 - $30.91 $476,315 - $624,382	20,200 Added 6.36%	338,000 $8.94 Million
Q4 2021 Feb 14, 2022	BUY	$20.0 - $32.29 $4.35 Million - $7.02 Million	217,550 Added 217.01%	317,800 $10.1 Million
Q3 2021 Nov 16, 2021	BUY	$16.48 - $27.23 $1.65 Million - $2.73 Million	100,250 New	100,250 $2.21 Million
Q1 2021 May 18, 2021	SELL	$16.14 - $29.11 $5.7 Million - $10.3 Million	-353,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$11.4 - $18.36 $4.02 Million - $6.48 Million	352,800 Added 176400.0%	353,000 $6.19 Million
Q3 2020 Nov 16, 2020	BUY	$10.57 - $16.0 $2,114 - $3,200	200 New	200 $2,000

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.28B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.